Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 220

1.

Competitive binding between dynamic p53 transactivation subdomains to human MDM2 protein: implications for regulating the p53·MDM2/MDMX interaction.

Shan B, Li DW, Brüschweiler-Li L, Brüschweiler R.

J Biol Chem. 2012 Aug 31;287(36):30376-84. doi: 10.1074/jbc.M112.369793. Epub 2012 Jul 17.

2.

On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study.

ElSawy KM, Verma CS, Joseph TL, Lane DP, Twarock R, Caves LS.

Cell Cycle. 2013 Feb 1;12(3):394-404. doi: 10.4161/cc.23511. Epub 2013 Jan 16.

3.

Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor.

Qin L, Yang F, Zhou C, Chen Y, Zhang H, Su Z.

J Am Chem Soc. 2014 Dec 31;136(52):18023-33. doi: 10.1021/ja509223m. Epub 2014 Dec 17. Retraction in: J Am Chem Soc. 2015 Nov 18;137(45):14546.

PMID:
25453499
4.

MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin.

Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J.

J Biol Chem. 2006 Nov 3;281(44):33030-5. Epub 2006 Aug 11.

5.

A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination.

Ma J, Martin JD, Zhang H, Auger KR, Ho TF, Kirkpatrick RB, Grooms MH, Johanson KO, Tummino PJ, Copeland RA, Lai Z.

Biochemistry. 2006 Aug 1;45(30):9238-45.

PMID:
16866370
6.

Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies.

Joseph TL, Madhumalar A, Brown CJ, Lane DP, Verma CS.

Cell Cycle. 2010 Mar 15;9(6):1167-81. Epub 2010 Mar 15.

PMID:
20190571
7.

Molecular basis for the inhibition of p53 by Mdmx.

Popowicz GM, Czarna A, Rothweiler U, Szwagierczak A, Krajewski M, Weber L, Holak TA.

Cell Cycle. 2007 Oct 1;6(19):2386-92. Epub 2007 Oct 12.

PMID:
17938582
8.

Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft.

Showalter SA, Bruschweiler-Li L, Johnson E, Zhang F, Brüschweiler R.

J Am Chem Soc. 2008 May 21;130(20):6472-8. doi: 10.1021/ja800201j. Epub 2008 Apr 25.

PMID:
18435534
9.

Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.

Pazgier M, Liu M, Zou G, Yuan W, Li C, Li C, Li J, Monbo J, Zella D, Tarasov SG, Lu W.

Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4665-70. doi: 10.1073/pnas.0900947106. Epub 2009 Mar 2.

10.

Autoinhibition of MDMX by intramolecular p53 mimicry.

Chen L, Borcherds W, Wu S, Becker A, Schonbrunn E, Daughdrill GW, Chen J.

Proc Natl Acad Sci U S A. 2015 Apr 14;112(15):4624-9. doi: 10.1073/pnas.1420833112. Epub 2015 Mar 30.

11.

Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.

Xia M, Knezevic D, Tovar C, Huang B, Heimbrook DC, Vassilev LT.

Cell Cycle. 2008 Jun 1;7(11):1604-12. Epub 2008 Mar 17.

PMID:
18520179
12.

Targeting of p53 peptide analogues to anti-apoptotic Bcl-2 family proteins as revealed by NMR spectroscopy.

Shin JS, Ha JH, Chi SW.

Biochem Biophys Res Commun. 2014 Jan 17;443(3):882-7. doi: 10.1016/j.bbrc.2013.12.054. Epub 2013 Dec 14.

PMID:
24342622
13.

A site-directed mutagenesis study of the MdmX RING domain.

Egorova O, Mis M, Sheng Y.

Biochem Biophys Res Commun. 2014 May 16;447(4):696-701. doi: 10.1016/j.bbrc.2014.04.065. Epub 2014 Apr 19. Erratum in: Biochem Biophys Res Commun. 2015 Aug 7;463(4):1341. Mis, Monika [added].

PMID:
24755078
14.

Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX.

Phan J, Li Z, Kasprzak A, Li B, Sebti S, Guida W, Schönbrunn E, Chen J.

J Biol Chem. 2010 Jan 15;285(3):2174-83. doi: 10.1074/jbc.M109.073056. Epub 2009 Nov 12.

15.

Impact of the K24N mutation on the transactivation domain of p53 and its binding to murine double-minute clone 2.

Zhan YA, Wu H, Powell AT, Daughdrill GW, Ytreberg FM.

Proteins. 2013 Oct;81(10):1738-47. doi: 10.1002/prot.24310. Epub 2013 Jul 22.

16.

Identification of a second Nutlin-3 responsive interaction site in the N-terminal domain of MDM2 using hydrogen/deuterium exchange mass spectrometry.

Hernychova L, Man P, Verma C, Nicholson J, Sharma CA, Ruckova E, Teo JY, Ball K, Vojtesek B, Hupp TR.

Proteomics. 2013 Aug;13(16):2512-25. doi: 10.1002/pmic.201300029.

PMID:
23776060
17.

Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2.

Chee SM, Wongsantichon J, Soo Tng Q, Robinson R, Joseph TL, Verma C, Lane DP, Brown CJ, Ghadessy FJ.

PLoS One. 2014 Aug 12;9(8):e104914. doi: 10.1371/journal.pone.0104914. eCollection 2014.

18.

Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells.

Wade M, Li YC, Matani AS, Braun SM, Milanesi F, Rodewald LW, Wahl GM.

Oncogene. 2012 Nov 8;31(45):4789-97. doi: 10.1038/onc.2011.625. Epub 2012 Jan 23.

19.
20.

Extended string binding mode of the phosphorylated transactivation domain of tumor suppressor p53.

Okuda M, Nishimura Y.

J Am Chem Soc. 2014 Oct 8;136(40):14143-52. doi: 10.1021/ja506351f. Epub 2014 Sep 29.

PMID:
25216154
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk